More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$169099959
EPS
-9.07
P/E ratio
--
Price to sales
62.81
Dividend yield
--
Beta
3.22803
Previous close
$12.71
Today's open
$12.69
Day's range
$12.15 - $13.22
52 week range
$5.20 - $17.35
show more
CEO
Ram Aiyar
Employees
57
Headquarters
Cambridge, MA
Exchange
NASDAQ Capital Market
Shares outstanding
13725646
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Nov. 13, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of a non-statutory stock option to one newly hired employee.
GlobeNewsWire • Nov 13, 2026

Korro to Present at the 2026 Jefferies Global Healthcare Conference in London
CAMBRIDGE, Mass., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel Oligonucleotide Promoted Editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, Ph.D., Chief Executive Officer and President, will present at the 2026 Jefferies Global Healthcare Conference in London being held on November 16-19, 2026. Dr. Aiyar's presentation will take place on Thursday, November 19th at 8:00 AM GMT (3:00 AM ET).
GlobeNewsWire • Nov 6, 2026

Korro Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Started dosing healthy volunteers with KRRO-121 in the Phase 1/2 clinical trial (ANCHOR) Expect to dose participants with Urea Cycle Disorders (UCDs) in the first half of 2027 Anticipate reporting interim data in the second half of 2027 Achieved best-in-class preclinical data with SERPINA1 mRNA editing (>95%) with KRRO-111 Planned regulatory submission in the first half of 2027 Ended third quarter 2026 with $124.8 million in cash, cash equivalents and marketable securities, supporting a cash runway into the second half of 2028 CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today reported results for the third quarter ended September 30, 2026, and provided a corporate update.
GlobeNewsWire • Nov 5, 2026

Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?
Korro Bio, Inc. (KRRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Zacks Investment Research • Oct 23, 2026

Korro Reports Best-in-Class Preclinical Data for KRRO-111 Demonstrating Potential to Benefit Lung and Liver Manifestations of Alpha-1 Antitrypsin Deficiency
Repeat dose mouse studies achieved >95% SERPINA1 mRNA editing, sustained restoration of circulating functional M-AAT and increased total AAT by ~6-fold KRRO-111 reduced pathogenic hepatic Z-AAT by up to 95%, highlighting its potential to reduce toxic protein accumulation in the liver Best-in-class preclinical profile supports KRRO-111's potential to address both liver and lung manifestations of AATD; regulatory submission expected in the first half of 2027 CAMBRIDGE, Mass., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced preclinical results for its pipeline program KRRO-111 for the potential treatment of alpha-1 antitrypsin deficiency (AATD) delivered subcutaneously.
GlobeNewsWire • Oct 22, 2026

Korro Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced the grant of non-statutory stock options to two newly hired employees.
GlobeNewsWire • Oct 16, 2026

Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121
CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, announced today that the first cohort of participants has been dosed in its Phase 1/2 clinical trial for KRRO-121, the Company's GalNAc-conjugated RNA-editing oligonucleotide (REO) in development for the potential treatment of hyperammonemia in patients with urea cycle disorders (UCDs) and patients with hepatic encephalopathy (HE).
GlobeNewsWire • Oct 5, 2026

Korro to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Korro, Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today announced that Ram Aiyar, President & Chief Executive Officer will participate in the following investor conferences:
GlobeNewsWire • Aug 27, 2026

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy
Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks Investment Research • Aug 10, 2026

Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update
KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical trial in second half of 2026 Received Orphan Drug Designation from the European Medicines Agency (EMA) for KRRO-121 for patients with urea cycle disorders (UCDs) Nominated KRRO-111 as development candidate for the treatment of Alpha-1 Antitrypsin Deficiency (AATD); potential best-in-class therapeutic delivered subcutaneously (GalNAc-conjugated oligonucleotide) for a debilitating genetic condition impacting both the liver and lungs Ended second quarter 2026 with $137.9 million in cash, cash equivalents and marketable securities; provides sufficient resources to achieve value inflection points for multiple RNA editing programs including clinical data for KRRO-121 and KRRO-111; cash runway into the second half of 2028 CAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company leveraging a novel oligonucleotide promoted editing of RNA (OPERA®) platform to develop a new class of genetic medicines for rare and highly prevalent diseases, today reported results for the second quarter ended June 30, 2026, and provided a corporate update.
GlobeNewsWire • Aug 6, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Korro Bio Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.